SYNERGY: Custirsen in Poor-Prognosis mCRPC

Slideset - A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.
Source: Clinical Care Options Prostate Cancer - Category: Cancer & Oncology Source Type: research